TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07185269: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib/II Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Anti-BDCA2 Antibody SSGJ-626 in Subjects With Systemic Lupus Erythem

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 198 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,384,000

Rescue Site Savings

+$6,187,575

Unlock Full NCT07185269 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07185269 Rescue Dossier →